X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SANOFI INDIA ALKEM LABORATORIES/
SANOFI INDIA
 
P/E (TTM) x - 37.1 - View Chart
P/BV x 6.5 7.0 93.3% View Chart
Dividend Yield % 0.7 0.5 122.4%  

Financials

 ALKEM LABORATORIES   SANOFI INDIA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SANOFI INDIA
Dec-17
ALKEM LABORATORIES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,5894,945 32.1%   
Low Rs1,2323,901 31.6%   
Sales per share (Unadj.) Rs417.51,081.8 38.6%  
Earnings per share (Unadj.) Rs56.3141.6 39.8%  
Cash flow per share (Unadj.) Rs64.7185.9 34.8%  
Dividends per share (Unadj.) Rs12.7033.00 38.5%  
Dividend yield (eoy) %0.90.7 120.7%  
Book value per share (Unadj.) Rs292.9868.8 33.7%  
Shares outstanding (eoy) m119.5723.03 519.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.1 82.6%   
Avg P/E ratio x25.131.2 80.2%  
P/CF ratio (eoy) x21.823.8 91.6%  
Price / Book Value ratio x4.85.1 94.6%  
Dividend payout %22.623.3 96.8%   
Avg Mkt Cap Rs m168,653101,862 165.6%   
No. of employees `000NA3.2 0.0%   
Total wages/salary Rs m9,1713,685 248.9%   
Avg. sales/employee Rs ThNM7,691.9-  
Avg. wages/employee Rs ThNM1,137.7-  
Avg. net profit/employee Rs ThNM1,006.5-  
INCOME DATA
Net Sales Rs m49,91524,914 200.4%  
Other income Rs m1,645807 203.9%   
Total revenues Rs m51,56125,721 200.5%   
Gross profit Rs m8,4825,372 157.9%  
Depreciation Rs m1,0061,022 98.4%   
Interest Rs m67111 6,096.4%   
Profit before tax Rs m8,4515,146 164.2%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,886 85.2%   
Profit after tax Rs m6,7313,260 206.5%  
Gross profit margin %17.021.6 78.8%  
Effective tax rate %19.036.6 51.9%   
Net profit margin %13.513.1 103.1%  
BALANCE SHEET DATA
Current assets Rs m27,06214,432 187.5%   
Current liabilities Rs m15,3246,010 255.0%   
Net working cap to sales %23.533.8 69.6%  
Current ratio x1.82.4 73.5%  
Inventory Days Days6761 109.2%  
Debtors Days Days4128 144.9%  
Net fixed assets Rs m12,6107,991 157.8%   
Share capital Rs m239230 103.8%   
"Free" reserves Rs m34,49019,778 174.4%   
Net worth Rs m35,02720,008 175.1%   
Long term debt Rs m1,2120-   
Total assets Rs m54,38727,770 195.8%  
Interest coverage x13.6468.8 2.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.9 102.3%   
Return on assets %13.611.8 115.5%  
Return on equity %19.216.3 117.9%  
Return on capital %24.925.8 96.4%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,5636,306 104.1%   
Fx outflow Rs m3,0125,257 57.3%   
Net fx Rs m3,5521,049 338.6%   
CASH FLOW
From Operations Rs m7,2594,351 166.8%  
From Investments Rs m1,864-787 -236.9%  
From Financial Activity Rs m-9,273-1,884 492.2%  
Net Cashflow Rs m-1501,680 -8.9%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 33.1 14.4 229.9%  
FIIs % 0.0 14.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.5 -  
Shareholders   68,381 15,184 450.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PIRAMAL ENTERPRISES  ABBOTT INDIA  PLETHICO PHARMA  DR. REDDYS LAB  GSK PHARMA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day Deep in Red, RBI Governor Resigns, and Top Stocks in Action(Pre-Open)

On Monday, share markets in India opened on a negative note and ended the day in deep red after a volatile day of trading.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Dec 10, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS